Orexin-A vs Pemvidutide
Head-to-head comparison of Orexin-A (Hypocretin-1 (Orexin-A)) and Pemvidutide (Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Orexin-A | Pemvidutide |
|---|---|---|
| Category | Cognitive Enhancement | Weight Management |
| Full Name | Hypocretin-1 (Orexin-A) | Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 3562 Da | N/A |
| Half-Life | Minutes to <1 hour | Approximately 1 week |
| Amino Acids | 33 | N/A |
| Typical Dose | Research-only; no validated human dose | Trial-dependent; once-weekly SC titration |
| Route | Intracerebroventricular/Intranasal | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 42 | 18 |
| Research Status | Pre-clinical | Clinical |
Orexin-A Benefits
- ✓wakefulness
- ✓attention
- ✓memory consolidation
- ✓fatigue resistance
Pemvidutide Benefits
- ✓appetite suppression
- ✓body-weight reduction
- ✓improved liver-fat markers
- ✓better glycemic control
Orexin-A Dosing
Research-only i.c.v. microgram/nanomolar studies|intranasal experimental use|no established human protocol
Pemvidutide Dosing
once-weekly subcutaneous injection|gradual dose escalation|maintenance at tolerated trial dose
Orexin-A Side Effects
- ⚠insomnia
- ⚠headache
- ⚠blood pressure changes
Pemvidutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Orexin-A
Preclinical studies link orexin signaling to arousal, learning, and memory consolidation, making orexin-A a candidate for cognition-related research. It is not an approved cognitive enhancer and remains an experimental peptide.
Pemvidutide
Clinical studies have reported dose-dependent weight loss and favorable effects on liver fat and transaminases. It remains investigational and is not approved for obesity treatment.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.